Rani Therapeutics Holdings, Inc. Logo

Rani Therapeutics Holdings, Inc.

Develops a capsule to convert injectable biologics into oral pills for chronic diseases.

RANI | US

Overview

Corporate Details

ISIN(s):
US7530181004
LEI:
Country:
United States of America
Address:
2051 RINGWOOD AVENUE, 95131 SAN JOSE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics. The company has created the RaniPill® capsule, a proprietary and disruptive platform technology designed to convert injectable drugs, such as peptides, proteins, and antibodies, into oral pills. This technology aims to replace painful injections for patients with chronic diseases, potentially improving adherence and quality of life across a wide range of therapeutic areas. Rani's core business revolves around advancing its pipeline of oral biologic candidates through clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Rani Therapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Rani Therapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Rani Therapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.